(Adds details throughout) Oct 3 (Reuters) – Rocket Pharmaceuticals said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder. The therapy RP-L102 was being tested in patients with Fanconi anemia, characterized by impaired bone marrow function which leads to a decrease in the production of blood cells. The company said the move was driven by business strategy and not by concerns about the treatment safety or efficacy. Rocket said it will consider external partnership opportunities for RP-L102. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Parents can help youngsters regain their motivation by creating successes. Making their progress visible will…
Berlin (dpa) – Bread and baked goods top the list of food items we wind…
Check out these tips to get the best out of your air fryer, from how…
A gene-edited pig kidney kept a man off dialysis for nine months in a world…
Rome (PA Media/dpa) - Cases of diabetes develop earlier and are more severe in women who…
Berlin (dpa) - Municipalities in many places around the globe have at least one dedicated…